Alivus Life Sciences Ltd
Alivus Life Sciences Q2 Results 2026 (FY27) investor presentation: Revenue & Margins
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Guidance rank: #47 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Alivus Life Sciences Ltd Q2 FY27 key numbers
- Revenue
- Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY).
As stated in Alivus Life Sciences Ltd's Q2 FY27 investor presentation · published 29 Oct 2026. Reported figures, not investment advice.
Based on Alivus Life Sciences Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). EBITDA for Q2 FY27: ₹2,851 million, up 47.0% YoY - EBITDA Margin for Q2 FY27: 41.8%, up 880 bps YoY - Profit After Tax (PAT) for Q2 FY27: ₹1,968 million, up 51.3% YoY - Net Profit Margin for Q2
From Alivus Life Sciences Ltd's Q2 FY27 earnings-call transcript · updated 29 Oct 2026.
Revenue & Sales Performance
- Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY).
- Non-GPL business revenue grew 20.8% YoY, contributing 79% of total revenues.
- Generic API revenues grew 11.0% YoY in Q2 FY27.
- CDMO business revenue grew 79.9% YoY in Q2 FY27.
2 more points from Alivus Life Sciences Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Alivus Life Sciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Brownfield Expansion:
- Ankleshwar: Planned addition of ~100 KL capacity, operational by Q4 FY27.
- Dahej: Planned addition of ~160 KL capacity, operational by Q3 FY27.
- Greenfield Expansion (Solapur):
- Phase 1: ~340 KL (Intermediate block and Backward Integration), operational by Q3 FY27.
- Phase 2: ~125 KL (API/Pharma block), operational by Q4 FY27.
- Phase 3: Planned addition of ~535 KL, operational by FY29.
- Construction work of 465 KL capacity (Phases 1 and 2) underway at Solapur.
- Capacity expansion in Solapur to be calibrated based on volume demand.
2 more points from Alivus Life Sciences Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Alivus Life Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Alivus Life Sciences Ltd's call on order book
Create a free account to keep reading this call
Alivus Life Sciences Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹640 Cr, net profit ₹160 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Alivus Life Sciences Ltd's management said in earlier quarters
- Q2 FY26 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q1 FY26 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY
- Aarti Pharmalabs Ltd (Q2 FY27)
19,211.62 lakhs (~45.9% increase) . Key investor presentation takeaways from Aarti Pharmalabs Ltd's Q2 FY27 investor presentation — and how it ranks against sec
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Alivus Life Sciences Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Alivus Life Sciences Ltd Q2 FY27 results?
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). EBITDA for Q2 FY27: ₹2,851 million, up 47.0% YoY - EBITDA Margin for Q2 FY27: 41.8%, up 880 bps YoY - Profit After Tax (PAT) for Q2 FY27: ₹1,968 million, up 51.3% YoY - Net Profit Margin for Q2
What is Alivus Life Sciences Ltd share price analysis?
Alivus Life Sciences Ltd currently shows a neutral. The stock trades at a P/E of 27.6 with a market cap of ₹17,150 Cr. Investors should review the full earnings analysis for detailed insights.
Is Alivus Life Sciences Ltd planning capital expenditure?
Brownfield Expansion: - Ankleshwar: Planned addition of ~100 KL capacity, operational by Q4 FY27.
Keep Alivus Life Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.